Single Arm on the Tolerability of Weekly Nab-paclitaxel

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

Clinical Trial Description

This will be a non-randomized phase II study evaluating the safety and efficacy of weekly nab-paclitaxel for second-line treatment in 42 elderly patients, who are 70 years of age or greater with non-small cell lung cancer (NSLC). Patients will be required to have progressed on a single prior regimen. Nab-paclitaxel 100mg/m2 will be administered intravenously, weekly for 3 weeks of every 4-week cycle. After every two cycles of therapy, imaging will be performed to assess for response. Patients will be eligible to continue receiving therapy until the time of disease progression.

Primary Objectives To evaluate the tolerability of weekly nab-paclitaxel in older adults with advanced lung cancer who have progressed on at least 1 prior regimen after 6 cycles or 3 weeks after discontinuation of treatment, for those who come off treatment earlier.

Secondary Objectives To estimate overall survival To estimate progression-free survival To estimate the response rate

Correlative Objectives To explore baseline components of the Geriatric Assessment (GA) as predictors of chemotherapy tolerance and overall survival To explore the use of p16 measurements in the elderly as predictors of chemotherapy tolerance and overall survival To explore the impact of weekly nab-paclitaxel treatment on quality of life, as measured by Lung Cancer Symptom Scale (LCSS) and Functional Assessment of Cancer Therapy-Lung (FACT-L). ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non Small Cell Lung Cancer (NSCLC)

Clinical Trial Details

NCT number	NCT01702844
Study type	Interventional
Source	UNC Lineberger Comprehensive Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	June 25, 2013
Completion date	July 12, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204099` - Study of PX-866 and Docetaxel in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04083599` - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT00148798` - Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)	Phase 3
Recruiting	`NCT06026410` - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors	Phase 1
Completed	`NCT02988817` - Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT01005797` - Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers	Phase 1
Recruiting	`NCT00637910` - Tarceva Italian Lung Optimization tRial	Phase 3
Active, not recruiting	`NCT03447678` - Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.	Phase 2
Completed	`NCT02456246` - Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT	N/A
Completed	`NCT02014324` - Single Scope Staging of Lung Cancer With Endosonography	N/A
Terminated	`NCT01741155` - Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)	Phase 2
Completed	`NCT01594398` - Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT01323062` - Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects	Phase 1
Active, not recruiting	`NCT04772989` - A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	Phase 1
Completed	`NCT00492206` - Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC	Phase 2
Completed	`NCT00820417` - Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib	Phase 1
Completed	`NCT02639026` - Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	Phase 1
Completed	`NCT01282437` - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC	Phase 3
Active, not recruiting	`NCT04721015` - Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors	Phase 1
Not yet recruiting	`NCT05473156` - A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies	Phase 1/Phase 2